AZ’s Tagrisso Soars in Phase 3

AstraZeneca’s lung cancer candidate Tagrisso succeeded in a Phase 3 trial, reaching its primary endpoint of superior progression-free survival versus standard platinum-based doublet chemotherapy.

The 400-patient trial assessed the drug in patients with EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer.

The drug was tested as a second-line treatment option if the cancer continues to progress following tyrosine kinase inhibitor therapy.